[{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET01-01 Antireceptors,,"},{"Key":"Keywords","Value":"Tumor associated macrophages,Cancer immunotherapy,Immune checkpoint,Antibody,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>K. B. Wicher<\/b>, M. Haneklaus, M. Lopez-Yrigoyen, A. Poindron, C. Rodriguez-Seoane, M. Fransen, C. Payton, S. M. Guillame, L. Cassetta, S. Myatt, C. Ries; <br\/>MACOMICS LTD, Edinburgh, United Kingdom","CSlideId":"","ControlKey":"0d7ec507-148f-4320-8afb-0de5e54e13d4","ControlNumber":"10625","DisclosureBlock":"&nbsp;<b>K. B. Wicher, <\/b> None..<br><b>M. Haneklaus, <\/b> None..<br><b>M. Lopez-Yrigoyen, <\/b> None..<br><b>A. Poindron, <\/b> None..<br><b>C. Rodriguez-Seoane, <\/b> None..<br><b>M. Fransen, <\/b> None..<br><b>C. Payton, <\/b> None..<br><b>S. M. Guillame, <\/b> None..<br><b>L. Cassetta, <\/b> None..<br><b>S. Myatt, <\/b> None..<br><b>C. Ries, <\/b> None.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10451","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"1","PosterboardNumber":"1","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB040","PresenterBiography":null,"PresenterDisplayName":"Krzysztof Wicher","PresenterKey":"853e5bd4-f79d-4508-8564-efde756f67d7","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB040. MACO-355, a unique pan-LILR monoclonal antibody for cancer therapy, re-programs and stimulates immuno-suppressive macrophages in a novel ligand-binding blocking independent manner.","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"597","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"MACO-355, a unique pan-LILR monoclonal antibody for cancer therapy, re-programs and stimulates immuno-suppressive macrophages in a novel ligand-binding blocking independent manner.","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET01-03 Growth factor receptors and other surface antigens as targets for therapy,,"},{"Key":"Keywords","Value":"ROR1,Protein-drug conjugate (PDC),Patient-derived xenograft (PDX) models,Biomarkers,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>A. N. Cranston<\/b><sup>1<\/sup>, M. Wappett<sup>2<\/sup>, E. G. McLean<sup>1<\/sup>, C. Saladino<sup>1<\/sup>, A. McCann<sup>1<\/sup>, W.-W. Kung<sup>1<\/sup>, J. Thom<sup>3<\/sup>, P. Trumper<sup>3<\/sup>, A. Porter<sup>4<\/sup>, C. Barelle<sup>4<\/sup>, T. Harrison<sup>1<\/sup>, G. Cotton<sup>3<\/sup>; <br\/><sup>1<\/sup>Almac Discovery Ltd., Belfast, United Kingdom, <sup>2<\/sup>Almac Discovery Ltd., Manchester, United Kingdom, <sup>3<\/sup>Almac Discovery Ltd., Edinburgh, United Kingdom, <sup>4<\/sup>Elasmogen Ltd., Aberdeen, United Kingdom","CSlideId":"","ControlKey":"0b327b79-e120-487a-abe6-6a0f291dc6b1","ControlNumber":"10622","DisclosureBlock":"&nbsp;<b>A. N. Cranston, <\/b> None..<br><b>M. Wappett, <\/b> None..<br><b>E. G. McLean, <\/b> None..<br><b>C. Saladino, <\/b> None..<br><b>A. McCann, <\/b> None..<br><b>W. Kung, <\/b> None..<br><b>J. Thom, <\/b> None..<br><b>P. Trumper, <\/b> None..<br><b>A. Porter, <\/b> None..<br><b>C. Barelle, <\/b> None..<br><b>T. Harrison, <\/b> None..<br><b>G. Cotton, <\/b> None.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10452","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"2","PosterboardNumber":"2","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB041","PresenterBiography":null,"PresenterDisplayName":"Aaron Cranston, BS;PhD","PresenterKey":"dbec312d-a141-4344-9429-9d91fe81b9a2","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB041. Exploiting a multi-center pre-clinical mouse PDX mini trial to identify new clinical opportunities for protein-drug conjugates (PDCs) targeting ROR1","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"597","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Exploiting a multi-center pre-clinical mouse PDX mini trial to identify new clinical opportunities for protein-drug conjugates (PDCs) targeting ROR1","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET01-03 Growth factor receptors and other surface antigens as targets for therapy,,"},{"Key":"Keywords","Value":"Fibroblast growth factor receptor 4  (FGFR-4),Antibody-drug conjugate (ADC),Rhabdomyosarcoma,Breast cancer,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>M. Tian<\/b><sup>1<\/sup>, K. Jia<sup>1<\/sup>, J. T. Wu<sup>1<\/sup>, J. S. Wei<sup>1<\/sup>, A. T. Cheuk<sup>1<\/sup>, Z. Zhang<sup>1<\/sup>, E. G. Pope<sup>1<\/sup>, B. Shor<sup>2<\/sup>, L. Tumey<sup>3<\/sup>, J. Khan<sup>1<\/sup>; <br\/><sup>1<\/sup>National Cancer Institute, Bethesda, MD, <sup>2<\/sup>Manhattan BioSolutions, Inc., New York, NY, <sup>3<\/sup>School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Binghamton, NY","CSlideId":"","ControlKey":"9f602bdd-56af-4502-a0fa-ab15aaeee94e","ControlNumber":"10684","DisclosureBlock":"&nbsp;<b>M. Tian, <\/b> None..<br><b>K. Jia, <\/b> None..<br><b>J. T. Wu, <\/b> None..<br><b>J. S. Wei, <\/b> None.&nbsp;<br><b>A. T. Cheuk, <\/b> <br><b>Hansoh Bio<\/b> Employment.<br><b>Z. Zhang, <\/b> None..<br><b>E. G. Pope, <\/b> None.&nbsp;<br><b>B. Shor, <\/b> <br><b>Manhattan BioSolutions, Inc.<\/b> Employment.<br><b>L. Tumey, <\/b> None..<br><b>J. Khan, <\/b> None.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10453","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"3","PosterboardNumber":"3","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB042","PresenterBiography":null,"PresenterDisplayName":"Meijie Tian, PhD","PresenterKey":"f8293535-d311-41d7-b8e1-16009060b8d4","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB042. A potent FGFR4-targeted antibody-drug conjugate therapy for patients with rhabdomyosarcoma and other cancers expressing FGFR4","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"597","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A potent FGFR4-targeted antibody-drug conjugate therapy for patients with rhabdomyosarcoma and other cancers expressing FGFR4","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET01-03 Growth factor receptors and other surface antigens as targets for therapy,,"},{"Key":"Keywords","Value":"Antibody-drug conjugate (ADC),Bispecific ADC,EGFR,cMet,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>W. Wang<\/b>, J. Li, L. Ma, M. Xu, Q. Yin; <br\/>VelaVigo (Shanghai) Limited, Shanghai, China","CSlideId":"","ControlKey":"bba596af-fa57-4d4d-9aea-4aaa741bd2e6","ControlNumber":"9776","DisclosureBlock":"&nbsp;<b>W. Wang, <\/b> None..<br><b>J. Li, <\/b> None..<br><b>L. Ma, <\/b> None..<br><b>M. Xu, <\/b> None..<br><b>Q. Yin, <\/b> None.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10454","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"4","PosterboardNumber":"4","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB043","PresenterBiography":null,"PresenterDisplayName":"Wei (Vivian) Wang, PhD","PresenterKey":"11404dee-4652-468f-b0df-7da2b41b513a","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB043. VBC101-F11: An innovative EGFR\/cMet bispecific antibody drug conjugate (ADC) targeting key oncogenic drivers in solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"597","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"VBC101-F11: An innovative EGFR\/cMet bispecific antibody drug conjugate (ADC) targeting key oncogenic drivers in solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET01-03 Growth factor receptors and other surface antigens as targets for therapy,,"},{"Key":"Keywords","Value":"HER2,T cell engager,Immunotherapy,Oncogenic mutation,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>I. Bang<\/b><sup>1<\/sup>, T. Hattori<sup>1<\/sup>, N. Leloup<sup>1<\/sup>, A. Corrado<sup>1<\/sup>, A. Nyamaa<sup>1<\/sup>, A. Koide<sup>1<\/sup>, K. Geles<sup>2<\/sup>, E. Buck<sup>2<\/sup>, S. Koide<sup>1<\/sup>; <br\/><sup>1<\/sup>NYU Grossman School of Medicine, New York, NY, <sup>2<\/sup>Black Diamond Therapeutics, New York, NY","CSlideId":"","ControlKey":"f3a07ded-fef2-463f-8d5b-3b20c45ab7c6","ControlNumber":"10330","DisclosureBlock":"<b>&nbsp;I. Bang, <\/b> <br><b>New York University<\/b> Patent, Listed as inventors of a provisional patent application filed by New York University on technology described in this abstract. <br><b>T. Hattori, <\/b> <br><b>New York University<\/b> Patent, listed as inventors of a provisional patent application filed by New York University on technology described in this abstract. <br><b>N. Leloup, <\/b> <br><b>New York University<\/b> Patent, listed as inventors of a provisional patent application filed by New York University on technology described in this abstract.<br><b>A. Corrado, <\/b> None..<br><b>A. Nyamaa, <\/b> None.&nbsp;<br><b>A. Koide, <\/b> <br><b>New York University<\/b> Patent, are listed as inventors of a provisional patent application filed by New York University on technology described in this abstract. <br><b>K. Geles, <\/b> <br><b>Black Diamond Therapeutcis<\/b> Employment, Former Employee. <br><b>E. Buck, <\/b> <br><b>Black Diamond Therapeutcis<\/b> Employment, Current Employee. <br><b>S. Koide, <\/b> <br><b>New York University<\/b> Patent, listed as inventors of a provisional patent application filed by New York University on technology described in this abstract. <br><b>Aethon Therapeutics<\/b> Stock, Other Business Ownership, Grant\/Contract, Co-founder of, holds equity, receives consulting fee from Aethon Therapeutics and have received reserach funding from Aethon as well.. <br><b>Revalia Bio<\/b> Stock, Other Business Ownership, Co-founder of and holds equity in Revalia Bio.. <br><b>Argenx BVBA<\/b> Grant\/Contract. <br><b>Black Diamond Therapeutics<\/b> Grant\/Contract. <br><b>Puretech Health<\/b> Grant\/Contract.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10455","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"5","PosterboardNumber":"5","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB044","PresenterBiography":null,"PresenterDisplayName":"Injin Bang, PhD","PresenterKey":"8d28f7fa-3065-4c33-97dc-e49cb4ec40ad","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB044. Selective therapeutic antibodies against oncogenic mutations of the HER2 extracellular region","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"597","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Selective therapeutic antibodies against oncogenic mutations of the HER2 extracellular region","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET01-03 Growth factor receptors and other surface antigens as targets for therapy,,"},{"Key":"Keywords","Value":"Antibody-drug conjugate (ADC),ALPP \/ ALPPL2,Targeted drug delivery,Bispecific antibody,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>G. Cotton<\/b><sup>1<\/sup>, E. G. McLean<sup>2<\/sup>, P. Trumper<sup>1<\/sup>, M. Wappett<sup>3<\/sup>, S. Gatdula<sup>2<\/sup>, S. Bell<sup>1<\/sup>, G. Papadakos<sup>1<\/sup>, K. Lucas<sup>1<\/sup>, S. Burton<sup>2<\/sup>, C. Saladino<sup>2<\/sup>, G. Parau<sup>2<\/sup>, A. McCann<sup>2<\/sup>, J. Thom<sup>1<\/sup>, A. N. Cranston<sup>2<\/sup>, T. Harrison<sup>2<\/sup>; <br\/><sup>1<\/sup>ALMAC DISCOVERY LIMITED, Edinburgh, United Kingdom, <sup>2<\/sup>ALMAC DISCOVERY LIMITED, Belfast, United Kingdom, <sup>3<\/sup>ALMAC DISCOVERY LIMITED, Manchester, United Kingdom","CSlideId":"","ControlKey":"2178875f-d656-4c7a-a25d-550b9e5f4205","ControlNumber":"10509","DisclosureBlock":"&nbsp;<b>G. Cotton, <\/b> None..<br><b>E. G. McLean, <\/b> None..<br><b>P. Trumper, <\/b> None..<br><b>M. Wappett, <\/b> None..<br><b>S. Gatdula, <\/b> None..<br><b>S. Bell, <\/b> None..<br><b>G. Papadakos, <\/b> None..<br><b>K. Lucas, <\/b> None..<br><b>S. Burton, <\/b> None..<br><b>C. Saladino, <\/b> None..<br><b>G. Parau, <\/b> None..<br><b>A. McCann, <\/b> None..<br><b>J. Thom, <\/b> None..<br><b>A. N. Cranston, <\/b> None..<br><b>T. Harrison, <\/b> None.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10456","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"6","PosterboardNumber":"6","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB045","PresenterBiography":null,"PresenterDisplayName":"Graham Cotton, PhD","PresenterKey":"ef11bbee-71c2-4d94-b5a1-430874489a36","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB045. Exploiting biparatopic binding to deliver novel, differentiated ALPP\/ALPPL2 targeting protein drug conjugates","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"597","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Exploiting biparatopic binding to deliver novel, differentiated ALPP\/ALPPL2 targeting protein drug conjugates","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET01-03 Growth factor receptors and other surface antigens as targets for therapy,,"},{"Key":"Keywords","Value":"Lysosome,Receptor tyrosine kinase (RTK),EGFR,Colorectal cancer,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"D. Kim, A. Zhu, <b>J. Hong<\/b>; <br\/>Daegu Catholic University School of Medicine, Daegu, Korea, Republic of","CSlideId":"","ControlKey":"9d89edc2-6924-4d2e-9829-a3b4dcfdffb3","ControlNumber":"10570","DisclosureBlock":"&nbsp;<b>D. Kim, <\/b> None..<br><b>A. Zhu, <\/b> None..<br><b>J. Hong, <\/b> None.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10457","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"7","PosterboardNumber":"7","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB046","PresenterBiography":null,"PresenterDisplayName":"Jaewoo Hong, DVM;PhD","PresenterKey":"14a480fe-a658-4552-ae00-0e6eb10cdf43","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB046. Treatment of EGFR-mediated tumors via lysosome activity regulation","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"597","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Treatment of EGFR-mediated tumors via lysosome activity regulation","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET01-04 Oncogenes, tumor suppressor genes, and gene products as targets for therapy,,"},{"Key":"Keywords","Value":"Head and neck squamous cell carcinoma,Oncogene,Cancer stem cell,Carcinogenesis,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>M. Sundaresan<\/b>, X. Cheng, C. WIng, A. von Kumberg, E. Jochum, A. Singh, J. Kainov, P. Zhao, M. Sidahmed, A. T. Pearson, A. J. Rosenberg, N. Agrawal, L. Shen, E. Izumchenko; <br\/>University of Chicago, Chicago, IL","CSlideId":"","ControlKey":"ccf4087d-3680-4122-81e3-ebb6ffd11e07","ControlNumber":"10510","DisclosureBlock":"&nbsp;<b>M. Sundaresan, <\/b> None..<br><b>X. Cheng, <\/b> None..<br><b>C. WIng, <\/b> None..<br><b>A. von Kumberg, <\/b> None..<br><b>E. Jochum, <\/b> None..<br><b>A. Singh, <\/b> None..<br><b>J. Kainov, <\/b> None..<br><b>P. Zhao, <\/b> None..<br><b>M. Sidahmed, <\/b> None..<br><b>A. T. Pearson, <\/b> None..<br><b>A. J. Rosenberg, <\/b> None..<br><b>N. Agrawal, <\/b> None..<br><b>L. Shen, <\/b> None..<br><b>E. Izumchenko, <\/b> None.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10458","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"8","PosterboardNumber":"8","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB047","PresenterBiography":null,"PresenterDisplayName":"Manu Sundaresan, No Degree","PresenterKey":"641f3fcc-67f4-4e81-a52c-6edc3820fc11","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB047. Pdcd10 is a promising therapeutic target for head and neck squamous cell carcinoma","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"597","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Pdcd10 is a promising therapeutic target for head and neck squamous cell carcinoma","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET01-04 Oncogenes, tumor suppressor genes, and gene products as targets for therapy,,"},{"Key":"Keywords","Value":"p53,mRNA,Tumor suppressor,Apoptosis,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Y. Heo<\/b>, S.-H. Shin, Y. Han, C. Lim, I. Kim, J. Lee, G. Lee, S. Jeong, Y. Kim, J. Byun, D. Kim, I. Choi; <br\/>Hanmi Pharmaceutical Co., Ltd., Seoul, Korea, Republic of","CSlideId":"","ControlKey":"f0276f1b-017d-4182-a0cb-9f0431cb6b29","ControlNumber":"10339","DisclosureBlock":"<b>&nbsp;Y. Heo, <\/b> <br><b>Hanmi Pharmaceutical Co., Ltd.<\/b> Employment. <br><b>S. Shin, <\/b> <br><b>Hanmi Pharmaceutical Co., Ltd.<\/b> Employment. <br><b>Y. Han, <\/b> <br><b>Hanmi Pharmaceutical Co., Ltd.<\/b> Employment. <br><b>C. Lim, <\/b> <br><b>Hanmi Pharmaceutical Co., Ltd.<\/b> Employment. <br><b>I. Kim, <\/b> <br><b>Hanmi Pharmaceutical Co., Ltd.<\/b> Employment. <br><b>J. Lee, <\/b> <br><b>Hanmi Pharmaceutical Co., Ltd.<\/b> Employment. <br><b>G. Lee, <\/b> <br><b>Hanmi Pharmaceutical Co., Ltd.<\/b> Employment. <br><b>S. Jeong, <\/b> <br><b>Hanmi Pharmaceutical Co., Ltd.<\/b> Employment. <br><b>Y. Kim, <\/b> <br><b>Hanmi Pharmaceutical Co., Ltd.<\/b> Employment. <br><b>J. Byun, <\/b> <br><b>Hanmi Pharmaceutical Co., Ltd.<\/b> Employment. <br><b>D. Kim, <\/b> <br><b>Hanmi Pharmaceutical Co., Ltd.<\/b> Employment. <br><b>I. Choi, <\/b> <br><b>Hanmi Pharmaceutical Co., Ltd.<\/b> Employment.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10459","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"9","PosterboardNumber":"9","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB048","PresenterBiography":null,"PresenterDisplayName":"Yong Ho Heo","PresenterKey":"4422d620-9d65-4562-a8a9-d917f6c84c2c","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB048. Unleashing the power of p53 mRNA therapeutics to suppress proliferation of p53 mutant tumors","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"597","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Unleashing the power of p53 mRNA therapeutics to suppress proliferation of p53 mutant tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET01-04 Oncogenes, tumor suppressor genes, and gene products as targets for therapy,,"},{"Key":"Keywords","Value":"Natural products,Long noncoding RNA,Lung cancer: non-small cell,Therapeutics,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>S. Shi<\/b>, Z. Zhang, J. Li, H. Tu, M. Costa; <br\/>NYU Grossman School of Medicine, New York, NY","CSlideId":"","ControlKey":"2a551076-e7f3-42a8-84ac-4eed1be907a8","ControlNumber":"9861","DisclosureBlock":"&nbsp;<b>S. Shi, <\/b> None..<br><b>Z. Zhang, <\/b> None..<br><b>J. Li, <\/b> None..<br><b>H. Tu, <\/b> None..<br><b>M. Costa, <\/b> None.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10460","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"10","PosterboardNumber":"10","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB049","PresenterBiography":null,"PresenterDisplayName":"Sophia Shi, No Degree","PresenterKey":"445b6b0a-d78c-436c-8dec-d993fedf18a3","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB049. Isoharpontigenin inhibits migration and invasion of lung cancer cells through MEG3\/EGFR pathway","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"597","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Isoharpontigenin inhibits migration and invasion of lung cancer cells through MEG3\/EGFR pathway","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET01-04 Oncogenes, tumor suppressor genes, and gene products as targets for therapy,,"},{"Key":"Keywords","Value":"BRAF,Thyroid cancer,Quantitative real-time polymerase chain reaction (qRT-PCR),,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>A. Ross Orozco<\/b><sup>1<\/sup>, E. Arámbula Meraz<sup>1<\/sup>, A. Gastelum Quiroz<sup>1<\/sup>, F. Luque Ortega<sup>1<\/sup>, E. García Alvarez<sup>2<\/sup>, M. Álvarez Arrazola<sup>3<\/sup>, K. Morales Hernández<sup>1<\/sup>, N. García Magallanes<sup>4<\/sup>; <br\/><sup>1<\/sup>Universidad Autónoma de Sinaloa, Culiacán, Mexico, <sup>2<\/sup>Instituto Mexicano del Seguro Social, Mazatlán, Mexico, <sup>3<\/sup>Álvarez & Arrazola Radiólogos, Mazatlán, Mexico, <sup>4<\/sup>Universidad Politécnica de Sinaloa, Mazatlán, Mexico","CSlideId":"","ControlKey":"a4e218d7-981a-4a69-aa76-90b1017837a1","ControlNumber":"10487","DisclosureBlock":"&nbsp;<b>A. Ross Orozco, <\/b> None..<br><b>E. Arámbula Meraz, <\/b> None..<br><b>A. Gastelum Quiroz, <\/b> None..<br><b>F. Luque Ortega, <\/b> None..<br><b>E. García Alvarez, <\/b> None..<br><b>M. Álvarez Arrazola, <\/b> None..<br><b>K. Morales Hernández, <\/b> None..<br><b>N. García Magallanes, <\/b> None.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10461","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"11","PosterboardNumber":"11","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB050","PresenterBiography":null,"PresenterDisplayName":"Andrea Ross Orozco, BS","PresenterKey":"bc85ecb2-1098-43b7-999a-adf16729ce8d","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB050. BRAF V600E is associated with the upregulation of CLDN1 in thyroid cancer","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"597","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"BRAF V600E is associated with the upregulation of CLDN1 in thyroid cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET01-05 Protein kinases and phosphatases as targets for therapy,,"},{"Key":"Keywords","Value":"Breast cancer,Protein kinase C,Tamoxifen,Structure-activity relationships,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>S. Sarkar Bhattacharya<\/b>, H. V. Huynh, J. K. Farmakes, T. L. Witter, E. S. Bruinsma, S. Jayaraman, A. T. Q. Cong, J. R. Hawse, M. P. Goetz, M. J. Schellenberg; <br\/>Mayo Clinic, Rochester, MN","CSlideId":"","ControlKey":"22c99d99-db57-4b93-8db1-256ee7003794","ControlNumber":"10821","DisclosureBlock":"&nbsp;<b>S. Sarkar Bhattacharya, <\/b> None..<br><b>H. V. Huynh, <\/b> None..<br><b>J. K. Farmakes, <\/b> None..<br><b>T. L. Witter, <\/b> None..<br><b>E. S. Bruinsma, <\/b> None..<br><b>S. Jayaraman, <\/b> None..<br><b>A. T. Q. Cong, <\/b> None.&nbsp;<br><b>J. R. Hawse, <\/b> <br><b>ATOSSA Therapeutics<\/b> Grant\/Contract. <br><b>M. P. Goetz, <\/b> <br><b>Research to Practice (6\/2022),Research to Practice (10\/2022),Clinical Education Alliance (2\/2021),Medscape (12\/2021),MJH Life Sciences (8\/2022),Total Health Conferencing (1\/2023),Curio Science (1\/20)<\/b> Other, Personal Fess. <br><b>ARC Therapeutics,AstraZeneca,Biotheranostics,Biotheryx,Blueprint Medicines,Engage Health Media,Lilly,Laekna,Novartis,Rna Diagnostics,Seattle Genetics,Sermonix,TerSera Therapeutics\/Ampity Steering Com<\/b> Other, Consulting fees to Mayo Clinic. <br><b>Lilly, Pfizer, Sermonix, Loxo, ATOSSA Therapeutics, AstraZeneca<\/b> Grant\/Contract. <br><b>Lilly (ESMO 10\/2023)<\/b> Travel.<br><b>M. J. Schellenberg, <\/b> None.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10462","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"12","PosterboardNumber":"12","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB051","PresenterBiography":null,"PresenterDisplayName":"Sayantani Bhattacharya, PhD","PresenterKey":"01831790-04ac-40a8-b68b-224cca493054","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB051. Protein kinase C beta 1 (PKC&#946;1) is allosterically inhibited and paradoxically translocated to the membrane by z-endoxifen","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"597","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Protein kinase C beta 1 (PKC&#946;1) is allosterically inhibited and paradoxically translocated to the membrane by z-endoxifen","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET01-05 Protein kinases and phosphatases as targets for therapy,,"},{"Key":"Keywords","Value":"HER2\/neu,Hypoxia,Protein phosphatase,Immunogenic cell death,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>B. G. Neel<\/b><sup>1<\/sup>, A. Bhardwaj<sup>2<\/sup>, M. Antonelli<sup>2<\/sup>, B. Ueberheide<sup>3<\/sup>; <br\/><sup>1<\/sup>NYU Langone Health Perlmutter Cancer Ctr., New York, NY, <sup>2<\/sup>Laura and Isaac Perlmutter Cancer Center, New York University Grossman School of Medicine, New York, NY, <sup>3<\/sup>3Department of Neurology, New York University Grossman School of Medicine, New York, NY, USA, New York, NY","CSlideId":"","ControlKey":"1a25c7c2-a632-421e-9198-ad33dbe6f04c","ControlNumber":"10668","DisclosureBlock":"<b>&nbsp;B. G. Neel, <\/b> <br><b>Lighthorse Therapeutics<\/b> holds equity in, and receives consulting fees from Lighthorse Therapeutics. <br><b>Aethon Therapeutics<\/b> holds equity in, and receives consulting fees Aethon Therapeutics. <br><b>Northern Biologics, LP<\/b> founder of, and holds equity in, Northern Biologics, LP. <br><b>Navire Pharma<\/b> founder of, and holds equity in, Navire Pharma. <br><b>Mirati and Repare Therapeutics<\/b> has sponsored research agreements with Mirati and Repare Therapeutics..<br><b>A. Bhardwaj, <\/b> None..<br><b>M. Antonelli, <\/b> None..<br><b>B. Ueberheide, <\/b> None.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10463","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"13","PosterboardNumber":"13","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB052","PresenterBiography":"","PresenterDisplayName":"Benjamin Neel, MD;PhD","PresenterKey":"f36614b2-dc65-43f4-ba4a-c118d5343c29","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB052. PTP1B inhibitors activate a novel hypoxia-induced inflammatory cell death pathway in breast cancer","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"597","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"PTP1B inhibitors activate a novel hypoxia-induced inflammatory cell death pathway in breast cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET01-05 Protein kinases and phosphatases as targets for therapy,,"},{"Key":"Keywords","Value":"BRAF,Inhibitors,RAF kinase,Ras,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. Hu<\/b>; <br\/>National Cancer Centre Singapore, Singapore, Singapore","CSlideId":"","ControlKey":"416e53f9-f819-4e36-ad14-17d3ecb509b9","ControlNumber":"10539","DisclosureBlock":"&nbsp;<b>J. Hu, <\/b> None.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10464","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"14","PosterboardNumber":"14","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB053","PresenterBiography":null,"PresenterDisplayName":"Jiancheng Hu, PhD","PresenterKey":"9336e6ea-5407-485d-afe1-643eebb8e30f","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB053. A novel BRAF-specific allosteric inhibitor that effectively targets acquired RAFi-resistant BRAF(V600E) cancers and RAS-mutated cancers in vitro and in vivo","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"597","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A novel BRAF-specific allosteric inhibitor that effectively targets acquired RAFi-resistant BRAF(V600E) cancers and RAS-mutated cancers in vitro and in vivo","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET01-05 Protein kinases and phosphatases as targets for therapy,,"},{"Key":"Keywords","Value":"Proteomics,Kinase inhibitors,Paclitaxel,Combination therapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"A. Omar Baryyan, <b>A. Fraga Timiraos<\/b>, K. Dejgaard, B. J. Jean-Claude; <br\/>McGill University Health Center, Montréal, QC, Canada","CSlideId":"","ControlKey":"68ee2321-5a21-44e9-ab68-00089c04ff1e","ControlNumber":"10942","DisclosureBlock":"&nbsp;<b>A. Omar Baryyan, <\/b> None..<br><b>A. Fraga Timiraos, <\/b> None..<br><b>K. Dejgaard, <\/b> None..<br><b>B. J. Jean-Claude, <\/b> None.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10465","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"15","PosterboardNumber":"15","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB054","PresenterBiography":null,"PresenterDisplayName":"Ana Belen Fraga Timiraos, PhD","PresenterKey":"34f8e99e-7ed0-4904-91ca-22ff312a9a04","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB054. A novel chemical proteomics approach toward the identification of kinase targets to sensitize tumour cells to the standard of care drug paclitaxel","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"597","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A novel chemical proteomics approach toward the identification of kinase targets to sensitize tumour cells to the standard of care drug paclitaxel","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET02-01 Antibody technologies,,"},{"Key":"Keywords","Value":"Antibody-drug conjugate (ADC),Bispecific antibody,Anticancer therapy,Drug discovery,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"J. Guan, X. Zhang, W. Wu, L. Cao, Z. Liao, T. Zhu, C. Liu, S. Zhou, J. Lu, N. Li, N. Luo, Y. Zhang, K. Dian, T. Chia, B. Chen, <b>K. He<\/b>; <br\/>Innovent Biologics, Suzhou, China","CSlideId":"","ControlKey":"1321c8ec-8af4-4aa2-be40-5b2153c96385","ControlNumber":"10494","DisclosureBlock":"&nbsp;<b>J. Guan, <\/b> None..<br><b>X. Zhang, <\/b> None..<br><b>W. Wu, <\/b> None..<br><b>L. Cao, <\/b> None..<br><b>Z. Liao, <\/b> None..<br><b>T. Zhu, <\/b> None..<br><b>C. Liu, <\/b> None..<br><b>S. Zhou, <\/b> None..<br><b>J. Lu, <\/b> None..<br><b>N. Li, <\/b> None..<br><b>N. Luo, <\/b> None..<br><b>Y. Zhang, <\/b> None..<br><b>K. Dian, <\/b> None..<br><b>T. Chia, <\/b> None..<br><b>B. Chen, <\/b> None..<br><b>K. He, <\/b> None.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10467","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"16","PosterboardNumber":"16","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB055","PresenterBiography":null,"PresenterDisplayName":"Kaijie He, PhD","PresenterKey":"5c861ce1-9062-4de0-a282-d77ee97bb134","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB055. IBI3001: A potentially first-in-class site-specifically conjugated B7-H3\/EGFR bispecific ADC for multiple solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"597","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"IBI3001: A potentially first-in-class site-specifically conjugated B7-H3\/EGFR bispecific ADC for multiple solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET02-01 Antibody technologies,,"},{"Key":"Keywords","Value":"Bispecific antibody,EGFR,Drug discovery,Anticancer therapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"J. Guan, S. Zhou, W. Wu, T. Zhu, L. Cao, M. Wu, N. Li, F. Fu, Z. Liao, S. Lin, Z. Liu, M. Zhu, N. Luo, Y. Zhang, T. Chia, B. Chen, <b>K. He<\/b>; <br\/>Innovent Biologics, Suzhou, China","CSlideId":"","ControlKey":"e6f0ffec-9f40-4ad3-a893-cb122006a06b","ControlNumber":"10350","DisclosureBlock":"&nbsp;<b>J. Guan, <\/b> None..<br><b>S. Zhou, <\/b> None..<br><b>W. Wu, <\/b> None..<br><b>T. Zhu, <\/b> None..<br><b>L. Cao, <\/b> None..<br><b>M. Wu, <\/b> None..<br><b>N. Li, <\/b> None..<br><b>F. Fu, <\/b> None..<br><b>Z. Liao, <\/b> None..<br><b>S. Lin, <\/b> None..<br><b>Z. Liu, <\/b> None..<br><b>M. Zhu, <\/b> None..<br><b>N. Luo, <\/b> None..<br><b>Y. Zhang, <\/b> None..<br><b>T. Chia, <\/b> None..<br><b>B. Chen, <\/b> None..<br><b>K. He, <\/b> None.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10468","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"17","PosterboardNumber":"17","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB056","PresenterBiography":null,"PresenterDisplayName":"Kaijie He, PhD","PresenterKey":"5c861ce1-9062-4de0-a282-d77ee97bb134","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB056. IBI334, a novel ADCC-enhanced B7-H3\/EGFR bispecific antibody, demonstrated potent pre-clinical efficacy in solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"597","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"IBI334, a novel ADCC-enhanced B7-H3\/EGFR bispecific antibody, demonstrated potent pre-clinical efficacy in solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET02-01 Antibody technologies,,"},{"Key":"Keywords","Value":"Antibody-drug conjugate (ADC),Anticancer therapy,Drug discovery,Cancer therapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"S. Zhou, X. Yao, J. Guan, K. Fei, J. Lu, W. Wu, Y. Liu, T. Zhu, Z. Liao, S. Chen, B. Chen, <b>K. He<\/b>; <br\/>Innovent Biologics, Suzhou, China","CSlideId":"","ControlKey":"bddf1e32-c8e2-43d8-8d62-8786ec01ef2a","ControlNumber":"10495","DisclosureBlock":"&nbsp;<b>S. Zhou, <\/b> None..<br><b>X. Yao, <\/b> None..<br><b>J. Guan, <\/b> None..<br><b>K. Fei, <\/b> None..<br><b>J. Lu, <\/b> None..<br><b>W. Wu, <\/b> None..<br><b>Y. Liu, <\/b> None..<br><b>T. Zhu, <\/b> None..<br><b>Z. Liao, <\/b> None..<br><b>S. Chen, <\/b> None..<br><b>B. Chen, <\/b> None..<br><b>K. He, <\/b> None.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10469","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"18","PosterboardNumber":"18","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB057","PresenterBiography":null,"PresenterDisplayName":"Kaijie He, PhD","PresenterKey":"5c861ce1-9062-4de0-a282-d77ee97bb134","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB057. Pre-clinical characterization of IBI343, a site-specifically conjugated anti-Claundin18.2 ADC, for treating solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"597","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Pre-clinical characterization of IBI343, a site-specifically conjugated anti-Claundin18.2 ADC, for treating solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET02-01 Antibody technologies,,"},{"Key":"Keywords","Value":"Antibody engineering,Antibody-drug conjugate (ADC),Preclinical,ADCC,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Y.-X. Yang<\/b><sup>1<\/sup>, L.-T. Ma<sup>1<\/sup>, P. Guo<sup>2<\/sup>; <br\/><sup>1<\/sup>College of Pharmaceutical Science, Zhejiang University of Technology (ZJUT), Hangzhou, Zhejiang 310000, China, Hangzhou, China, <sup>2<\/sup>Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310018, China, Hangzhou, China","CSlideId":"","ControlKey":"2e1cb38c-42ae-445c-94c6-215fda3058a2","ControlNumber":"10605","DisclosureBlock":"&nbsp;<b>Y. Yang, <\/b> None..<br><b>L. Ma, <\/b> None..<br><b>P. Guo, <\/b> None.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10470","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"19","PosterboardNumber":"19","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB058","PresenterBiography":null,"PresenterDisplayName":"YuXuan Yang","PresenterKey":"7898f42d-aa77-4fb8-9b6b-38e4ac2afb0e","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB058. N-glycan deglycosylation ameliorates anti-HER2 antibody drug conjugate-induced interstitial pneumonia in preclinical models","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"597","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"N-glycan deglycosylation ameliorates anti-HER2 antibody drug conjugate-induced interstitial pneumonia in preclinical models","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET02-01 Antibody technologies,,"},{"Key":"Keywords","Value":"Colorectal cancer,Antibody-drug conjugate (ADC),Topoisomerase I inhibitor,Exatecan,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>S.-J. Neuberth<\/b>, C. Orlik, A. Palfi, C. Mueller, H. Gruss, T. Hechler; <br\/>Heidelberg Pharma Research GmbH, Ladenburg, Germany","CSlideId":"","ControlKey":"e6587ee6-40ce-46ba-8d57-a09c79aabf10","ControlNumber":"10678","DisclosureBlock":"<b>&nbsp;S. Neuberth, <\/b> <br><b>Heidelberg Pharma Research GmbH<\/b> Employment, Stock Option. <br><b>C. Orlik, <\/b> <br><b>Heidelberg Pharma Research GmbH<\/b> Employment, Stock Option. <br><b>A. Palfi, <\/b> <br><b>Heidelberg Pharma Research GmbH<\/b> Employment, Stock Option. <br><b>C. Mueller, <\/b> <br><b>Heidelberg Pharma Research GmbH<\/b> Employment, Stock, Stock Option. <br><b>H. Gruss, <\/b> <br><b>Heidelberg Pharma Research GmbH<\/b> Employment, Stock Option. <br><b>T. Hechler, <\/b> <br><b>Heidelberg Pharma Research GmbH<\/b> Employment, Stock, Stock Option.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10471","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"20","PosterboardNumber":"20","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB059","PresenterBiography":null,"PresenterDisplayName":"Sarah-Jane Neuberth, PhD","PresenterKey":"088ec8cf-890f-4a8d-aea4-452219dd249b","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB059. Multimeric linker-exatecan-based ADC targeting guanylyl cyclase C (GCC) as novel therapeutic modality for treatment of colorectal cancer","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"597","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Multimeric linker-exatecan-based ADC targeting guanylyl cyclase C (GCC) as novel therapeutic modality for treatment of colorectal cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET02-01 Antibody technologies,,"},{"Key":"Keywords","Value":"KRAS,Antibody engineering,Mutation detection,Immunoassay,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"R. Serrano<sup>1<\/sup>, R. Wallace<sup>1<\/sup>, S. Bibikov<sup>1<\/sup>, M. Weiner<sup>2<\/sup>, <b>K. J. Harvey<\/b><sup>1<\/sup>; <br\/><sup>1<\/sup>Aviva Systems Biology, San Diego, CA, <sup>2<\/sup>AbbraTech, Branford, CT","CSlideId":"","ControlKey":"9ce253b3-68ad-4dc2-afb1-1192a7809ea6","ControlNumber":"9787","DisclosureBlock":"&nbsp;<b>R. Serrano, <\/b> None..<br><b>R. Wallace, <\/b> None..<br><b>S. Bibikov, <\/b> None..<br><b>M. Weiner, <\/b> None..<br><b>K. J. Harvey, <\/b> None.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10472","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"21","PosterboardNumber":"21","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB060","PresenterBiography":null,"PresenterDisplayName":"Kevin Harvey, PhD","PresenterKey":"2aecc305-c426-44aa-9705-95416c243f73","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB060. Engineering KRAS mutation-specific affinity binders: A new frontier in cancer research","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"597","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Engineering KRAS mutation-specific affinity binders: A new frontier in cancer research","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET02-03 Combination chemotherapies,,"},{"Key":"Keywords","Value":"Aurora kinase,Chemotherapy,Chemoresistance,Triple-negative breast cancer (TNBC),"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. Xu<\/b>, C. Liu, B. Ning, A. Kucukdagli, Y. Chen; <br\/>University of Alabama at Birmingham, Birmingham, AL","CSlideId":"","ControlKey":"d717fcaa-1657-4cc6-bc40-dd010e00d703","ControlNumber":"10516","DisclosureBlock":"&nbsp;<b>J. Xu, <\/b> None..<br><b>C. Liu, <\/b> None..<br><b>B. Ning, <\/b> None..<br><b>A. Kucukdagli, <\/b> None..<br><b>Y. Chen, <\/b> None.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10473","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"22","PosterboardNumber":"22","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB061","PresenterBiography":null,"PresenterDisplayName":"Jia Xu, PhD","PresenterKey":"7dfe6630-d05d-49e2-ac87-c05f04e08857","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB061. Aurora kinases inhibition enhances neoadjuvant chemotherapy response in triple negative breast cancer<b><\/b>","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"597","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Aurora kinases inhibition enhances neoadjuvant chemotherapy response in triple negative breast cancer<b><\/b>","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET02-04 Differentiation therapy,,"},{"Key":"Keywords","Value":"Gamma-delta lymphocytes,Epidermal growth factor receptor (EGFR),T cell engager,Cytotoxicity,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"J. Freedman<sup>1<\/sup>, G. Stevens<sup>1<\/sup>, J. Julie Hoong<sup>1<\/sup>, M. Tuna<sup>2<\/sup>, Y. Shi<sup>3<\/sup>, K. J. Seidl<sup>3<\/sup>, K. Galvin<sup>3<\/sup>, A. Hutton<sup>4<\/sup>, <b>A. Banerjee<\/b><sup>5<\/sup>; <br\/><sup>1<\/sup>Takeda Pharmaceuticals, London, United Kingdom, <sup>2<\/sup>Cambridge Innovation, Cambridge, United Kingdom, <sup>3<\/sup>Takeda Pharmaceuticals, Cambridge, MA, <sup>4<\/sup>Takeda Pharmaceuticals, Oncology Drug Discovery Unit, Cambridge, MA, <sup>5<\/sup>Takeda Pharmaceuticals, San Diego, CA","CSlideId":"","ControlKey":"53bdd1c0-b8a9-4c8e-b72b-63378d89f12c","ControlNumber":"10799","DisclosureBlock":"&nbsp;<b>J. Freedman, <\/b> None..<br><b>G. Stevens, <\/b> None..<br><b>J. Julie Hoong, <\/b> None..<br><b>M. Tuna, <\/b> None..<br><b>Y. Shi, <\/b> None..<br><b>K. J. Seidl, <\/b> None..<br><b>K. Galvin, <\/b> None..<br><b>A. Hutton, <\/b> None..<br><b>A. Banerjee, <\/b> None.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10474","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"23","PosterboardNumber":"23","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB062","PresenterBiography":null,"PresenterDisplayName":"Antara Banerjee","PresenterKey":"bc6028eb-bcb5-4117-940f-a8185c541479","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB062. ADT3_A potential first-in-class V&#948;1-engager for <i>in situ<\/i> activation of V&#948;1 &#947;&#948; T cells and enhanced cytotoxicity towards solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"597","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"ADT3_A potential first-in-class V&#948;1-engager for <i>in situ<\/i> activation of V&#948;1 &#947;&#948; T cells and enhanced cytotoxicity towards solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET02-08 Targeting the tumor microenvironment in drug development,,"},{"Key":"Keywords","Value":"HER2,T cell engager,Tumor microenvironment,Imaging,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>B. Stringer<\/b><sup>1<\/sup>, J. Chouitar<sup>1<\/sup>, J. Cerbone<sup>1<\/sup>, S. Fortin<sup>1<\/sup>, A. Ainbinder<sup>1<\/sup>, C. Kysilovsky<sup>2<\/sup>, B. Scott<sup>1<\/sup>, A. Banerjee<sup>2<\/sup>; <br\/><sup>1<\/sup>Takeda Pharmaceuticals, Cambridge, MA, <sup>2<\/sup>Takeda Pharmaceuticals, San Diego, CA","CSlideId":"","ControlKey":"611ce055-173c-4544-a037-e02082644d8b","ControlNumber":"10814","DisclosureBlock":"&nbsp;<b>B. Stringer, <\/b> None..<br><b>J. Chouitar, <\/b> None..<br><b>J. Cerbone, <\/b> None..<br><b>S. Fortin, <\/b> None..<br><b>A. Ainbinder, <\/b> None..<br><b>C. Kysilovsky, <\/b> None..<br><b>B. Scott, <\/b> None..<br><b>A. Banerjee, <\/b> None.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11671","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"24","PosterboardNumber":"24","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB063","PresenterBiography":null,"PresenterDisplayName":"BRADLEY STRINGER","PresenterKey":"1aa9856a-5998-4cba-9959-963ef1040a24","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB063. Anti-tumor activity in preclinical models utilizing a conditional bispecific redirected activation molecule (COBRA) targeting Her2","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"597","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Anti-tumor activity in preclinical models utilizing a conditional bispecific redirected activation molecule (COBRA) targeting Her2","Topics":null,"cSlideId":""}]